Venmax Drugs & Pharmaceuticals has informed about the Statement of Investor Complaints for the Quarter ended 30th June 2017 under regulation 13 (3) of the SEBI (LODR) Regulation 2015.
The above information is a part of company’s filings submitted to BSE.